THE EVALUATION OF THE IMMUN RESPONSE DUE TO HEPATITIS B VACCINES

Health care personnel are at increased risk of acquisition of Hepatitis B Virus, it is possible to be protected by vaccines produced against it. In this study 92 healthcare personnel with negative Hepatitis B markers were randomly divided into 2 groups. First generation recombinant Hepatitis B vaccine was administered the first group and Hepatits B vaccine was administered to the second group on the 0,1st,2nd months. Serum samples were taken from the cases on the 1st,2nd and 3rd months and were kept -20°C. Anti-HBs levels were measured by micro-ELISA. There was no statistical significance between both the geometrik mean titration (GMT) and the Anti-HBs levels of the two groups. A meaningful difference was not found in the capacity of antibody producing between the two vaccines (p>0.05). Although there wasn't a meaningful difference in the GMT levels and antibody producing capacity in both vaccines, 11% - 22% of the cases couldn't producing protective antibody levels and it is thought that antibody levels should be measured after Hepatitis B vaccination.

HEPATÝT B AÞILARINA KARÞI OLUÞAN ÝMMUN CEVABIN DEÐERLENDÝRÝLMESÝ

Saðlýk çalýþanlarý meslekleri nedeniyle Hepatit B Virüs bulaþým riski altýndadýrlar. Bu etkene kargý geliþtirilen aþýlar ile korunmak mümkündür. Bu çalýþmada, Hepatit B Virüs marker'larý negatif bulunan 92 saðlýk personeli randomize olarak iki gruba ayrýlmýþtýr. 1. gruba birinci kuþak rekombinant, 2. gruba plazma kaynaklý Hepatit B aþýsý 0., l.,2., aylarda yapýlmýþtýr. Bireylerden 1., 2., 3., aylarda serum örnekleri alýnarak -20°C de saklanmýþtýr. Anti-HBs düzeyleri mikro-ELISA yöntemi ile çalýþýlmýþtýr. Anti-HBs geometrik ortalama titrasyonu (GMT) deðerleri 1. ve 2. grupta ayrý ayrý incelendiðinde iki grup arasýnda GMT deðerleri ve antikor oluþturma yönünden anlamlý bir fark bulunmamýþtýr. Ýki aþý arasýnda 3 kez aþýlama sonrasý GMT deðerleri ve koruyucu düzeyde antikor oluþturma yönünden anlamlý bir fark bulunamamakla birlikte olgularýn %11-22 sinde koruyucu düzeyde antikor oluþmamasý aþýlama sonrasý antikor düzeylerinin kontrolü gerekliliðim düþündürdü.